Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Cancer Research and Clinical Oncology
Erschienen in: Journal of Cancer Research and Clinical Oncology 8/2022

13.05.2022 | Review – Clinical Oncology

Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer

verfasst von: Nicole M. Myer, Kohei Shitara, Hyun C. Chung, Florian Lordick, Ronan J. Kelly, Zsolt Szabo, Z. Alexander Cao, Stephen Leong, David H. Ilson, Wilko Weichert

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Despite new therapeutic options, advanced gastric cancer remains associated with a poor prognosis compared with other cancers. Recent gains in the treatment of gastric cancer were accompanied by the identification of novel biomarkers associated with various cellular pathways and corresponding diagnostic technologies. It is expected that the standardization of clinical workflow and technological refinements in biomarker assessment will support greater personalization and further improve treatment outcomes. In this article, we review the current state of prognostic and predictive biomarkers in gastric cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Arai T, Sakurai U, Sawabe M, Honma N, Aida J, Ushio Y et al (2013) Frequent microsatellite instability in papillary and solid-type, poorly differentiated adenocarcinomas of the stomach. Gastric Cancer 16(4):505–512PubMedCrossRef
Arnold A, Daum S, von Winterfeld M, Berg E, Hummel M, Horst D et al (2019) Analysis of NTRK expression in gastric and esophageal adenocarcinoma (AGE) with pan-TRK immunohistochemistry. Pathol Res Pract 215(11):152662PubMedCrossRef
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697PubMedCrossRef
Bartley AN, Washington MK, Ismaila N, Ajani JA (2017) HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline summary from the college of American pathologists, American society for clinical pathology, and American society of clinical oncology. J Oncol Pract 13(1):53–57PubMedCrossRef
Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Costa WL Jr et al (2011) Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 29(22):3030–3036PubMedCrossRef
Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW et al (2019) Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol 30(2):250–258PubMedCrossRef
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424PubMedCrossRef
Bristol Myers Squibb (2020) Opdivo (nivolumab) injection, for intravenous use. Prescribing information
Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517):202–209CrossRef
Catenacci DVT, Kang YK, Park H, Uronis HE, Lee KW, Ng MCH et al (2020) Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b–2 trial. Lancet Oncol 21(8):1066–1076PubMedCrossRef
Catenacci DV, Rosales M, Chung HC, Shen L, Moehler M et al (2021) MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncol 17(10):1155–1164PubMedCrossRef
Chaganty BKR, Qiu S, Gest A, Lu Y, Ivan C, Calin GA et al (2018) Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN γ secretion. Cancer Lett 430:47–56PubMedPubMedCentralCrossRef
Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E et al (2021) Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol 7(6):895–902PubMedPubMedCentralCrossRef
Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC et al (2020) A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer 23(3):510–519PubMedCrossRef
Cheng ML, Pectasides E, Hanna GJ, Parsons HA, Choudhury AD, Oxnard GR (2021) Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions. CA Cancer J Clin 71(2):176–190PubMedCrossRef
Cristescu R, Albright A, Qiu P, Mogg R, Lunceford J, Liu XQ et al (2017) Genomic determinants of response to pembrolizumab in gastric cancer. In: Presented at the Socieity for Immunotherapy of Cancer, November 8–12, 2017
Ding L, Lu Z, Lu Q, Chen YH (2013) The claudin family of proteins in human malignancy: a clinical perspective. Cancer Manag Res 5:367–375PubMedPubMedCentral
Emancipator K (2020) Keytruda and PD-L1: a real-world example of co-development of a drug with a predictive biomarker. AAPS J 23(1):5PubMedCrossRef
Eriksson J, Amonkar M, Al-Jassar G, Lambert J, Malmenäs M, Chase M et al (2020) Experience of mismatch repair/microsatellite instability (MMR/MSI) testing among patients with advanced/metastatic colorectal cancer in the US. Curr Med Res Opin 36(8):1355–1361PubMedCrossRef
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M et al (2018) Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 4(5):e180013PubMedPubMedCentralCrossRef
Galsky MD, Saci A, Szabo PM, Han GC, Grossfeld G, Collette S et al (2020) Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from CheckMate 275. Clin Cancer Res 26(19):5120–5128PubMedPubMedCentralCrossRef
Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19(9):1523–1529PubMedCrossRef
Grillo F, Fassan M, Sarocchi F, Fiocca R, Mastracci L (2016) HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice. World J Gastroenterol 22(26):5879–5887PubMedPubMedCentralCrossRef
Hagi T, Kurokawa Y, Kawabata R, Omori T, Matsuyama J, Fujitani K et al (2020) Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer. Br J Cancer 123(6):965–972PubMedPubMedCentralCrossRef
Hause RJ, Pritchard CC, Shendure J, Salipante SJ (2016) Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 22(11):1342–1350PubMedCrossRef
Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO et al (2016) Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC—a randomized phase III Trial. J Clin Oncol 34(5):443–451PubMedCrossRef
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C et al (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378(22):2093–2104PubMedPubMedCentralCrossRef
Heydt C, Rehker J, Pappesch R, Buhl T, Ball M, Siebolts U et al (2020) Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing. Sci Rep 10(1):11387PubMedPubMedCentralCrossRef
Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K et al (2017) PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay comparison project. J Thorac Oncol 12(2):208–222PubMedCrossRef
Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W et al (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52(7):797–805PubMedCrossRef
Huang RSP, Haberberger J, Severson E, Duncan DL, Hemmerich A, Edgerly C et al (2021) A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. Mod Pathol 34(2):252–263PubMedCrossRef
Hur JY, Chao J, Kim K, Kim ST, Kim KM, Klempner SJ et al (2020) High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. Pathol Res Pract 216(4):152878PubMedCrossRef
Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198(2–3):165–184PubMed
Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E et al (2012) Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 23(10):2656–2662PubMedCrossRef
Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C et al (2020) First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol 21(6):821–831PubMedPubMedCentralCrossRef
Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L et al (2021b) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294):27–40PubMedPubMedCentralCrossRef
Janjigian YY, Kawazoe A, Yanez PE, Luo S, Lonardi S, Kolesnik O et al (2021a) Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study. J Clin Oncol 39(15_suppl):Abstract 4013
Japanese Gastric Cancer Association (2020) Japanese gastric cancer treatment guidelines 2018 (5th ed). Gastric Cancer 24(1):1–21PubMedCentralCrossRef
Jun KH, Kim JH, Jung JH, Choi HJ, Chin HM (2014) Expression of claudin-7 and loss of claudin-18 correlate with poor prognosis in gastric cancer. Int J Surg 12(2):156–162PubMedCrossRef
Kelly RJ, Lee J, Bang YJ, Almhanna K, Blum-Murphy M, Catenacci DVT et al (2020) Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma. Clin Cancer Res 26(4):846–854PubMedCrossRef
Kijima T, Arigami T, Uenosono Y, Hiraki T, Yanagita S, Matsushita D et al (2020) Comparison of HER2 status before and after trastuzumab-based chemotherapy in patients with advanced gastric cancer. Anticancer Res 40(1):75–80PubMedCrossRef
Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS et al (2011) Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 18(10):2833–2840PubMedCrossRef
Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K et al (2018) Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 24(9):1449–1458PubMedCrossRef
Kubota Y, Kawazoe A, Sasaki A, Mishima S, Sawada K, Nakamura Y et al (2020) The impact of molecular subtype on efficacy of chemotherapy and checkpoint inhibition in advanced gastric cancer. Clin Cancer Res 26(14):3784–3790PubMedCrossRef
Kulangara K, Zhang N, Corigliano E, Guerrero L, Waldroup S, Jaiswal D et al (2019) Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med 143(3):330–337PubMedCrossRef
Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D et al (2020) Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol Cancer Ther 19(4):976–987PubMedCrossRef
Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H et al (2015) Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer 18(4):691–697PubMedCrossRef
Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F et al (2018) Comparative molecular analysis of gastrointestinal adenocarcinomas. Cancer Cell 33(4):721-735.e728PubMedPubMedCentralCrossRef
Liu X, Choi MG, Kim K, Kim KM, Kim ST, Park SH et al (2020) High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. Pathol Res Pract 216(4):152881PubMedCrossRef
Lordick F, Shitara K, Janjigian YY (2017) New agents on the horizon in gastric cancer. Ann Oncol 28(8):1767–1775PubMedCrossRef
Lu Y, Wu T, Sheng Y, Dai Y, Xia B, Xue Y (2020) Correlation between Claudin-18 expression and clinicopathological features and prognosis in patients with gastric cancer. J Gastrointest Oncol 11(6):1253–1260PubMedPubMedCentralCrossRef
Ma J, Li J, Qian M, Han W, Tian M, Li Z et al (2018) PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N). Diagn Pathol 13(1):91PubMedPubMedCentralCrossRef
Makiyama A, Sukawa Y, Kashiwada T, Kawada J, Hosokawa A, Horie Y et al (2020) Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study). J Clin Oncol 38(17):1919–1927PubMedCrossRef
Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K et al (2020a) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21(10):1353–1365PubMedCrossRef
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP et al (2020b) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38(1):1–10PubMedCrossRef
Maron SB, Chase LM, Lomnicki S, Kochanny S, Moore KL, Joshi SS et al (2019) Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. Clin Cancer Res 25(23):7098–7112PubMedPubMedCentralCrossRef
McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M et al (2021) High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 32(5):661–672PubMedCrossRef
Meléndez B, Van Campenhout C, Rorive S, Remmelink M, Salmon I, D’Haene N (2018) Methods of measurement for tumor mutational burden in tumor tissue. Transl Lung Cancer Res 7(6):661–667PubMedPubMedCentralCrossRef
Mishima S, Kawazoe A, Nakamura Y, Sasaki A, Kotani D, Kuboki Y et al (2019) Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. J Immunother Cancer 7(1):24PubMedPubMedCentralCrossRef
Moehler M, Shitara K, Garrido M, Salman P, Shen L, Wyrwicz L et al (2020a) LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. Ann Oncol 31:S1191CrossRef
Moehler MH, Dvorkin M, Ozguroglu M, Ryu MH, Muntean AS, Lonardi S et al (2020b) Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC). J Clin Oncol 38(4_suppl):278–278
Moehler M, Dvorkin M, Boku N, Özgüroğlu M, Ryu MH, Muntean AS et al (2021) Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results From JAVELIN gastric 100. J Clin Oncol 39(9):966–977PubMedCrossRef
Motoshima S, Yonemoto K, Kamei H, Morita M, Yamaguchi R (2018) Prognostic implications of HER2 heterogeneity in gastric cancer. Oncotarget 9(10):9262–9272PubMedPubMedCentralCrossRef
National Health Commission of the People’s Republic of China (2019) Chinese guidelines for diagnosis and treatment of gastric cancer 2018 (English version). Chin J Cancer Res 31(5):707–737PubMedPubMedCentralCrossRef
National Comprehensive Cancer Network (2021) NCCN Clinical Practice Guidelines in Oncolgy. Gastric Cancer. Version 4.2021. Plymouth Meeting, PA
Noske A, Ammann JU, Wagner DC, Denkert C, Lebeau A, Sinn P et al (2021) A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer. Histopathology 78(4):567–577PubMedCrossRef
Oh D-Y, Chung HC, Im YH, Yen CJ, Chao Y, Li Z et al (2020) ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: a phase 1B/2 trial-in-progress. J Clin Oncol 38(15_suppl):TPS3145
Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG (2008) Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 44(7):946–953PubMedCrossRef
Park KK, Yang SI, Seo KW, Yoon KY, Lee SH, Jang HK et al (2015) Correlations of human epithelial growth factor receptor 2 overexpression with MUC2, MUC5AC, MUC6, p53, and clinicopathological characteristics in gastric cancer patients with curative resection. Gastroenterol Res Pract 2015946359
Patel M, Siena S, Demetri G, Doebele R, Chae Y, Conkling P et al (2020) O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001). Ann Oncol 31(suppl 3):232–233CrossRef
Peng Z, Wei J, Wang F, Ying J, Deng Y, Gu K et al (2021) Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res 27(11):3069–3078PubMedCrossRef
Ricci AD, Rizzo A, Rojas Llimpe FL, Di Fabio F, De Biase D, Rihawi K (2021) Novel HER2-directed treatments in advanced gastric carcinoma: anotHER paradigm shift? Cancers (Basel) 13(7)
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124–128PubMedPubMedCentralCrossRef
Roche Products Limited (2021) Rozlytrek 100 mg hard capsules. Summary of product characteristics
Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F et al (2012) HER2 testing in gastric cancer: a practical approach. Mod Pathol 25(5):637–650PubMedCrossRef
Sahin U, Türeci Ö, Manikhas G, Lordick F, Rusyn A, Vynnychenko I et al (2021) FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol 32(5):609–619PubMedCrossRef
Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM et al (2014) Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study. J Clin Oncol 32(19):2039–2049PubMedCrossRef
Seo S, Ryu MH, Park YS, Ahn JY, Park Y, Park SR et al (2019) Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer 22(3):527–535PubMedCrossRef
Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA (2020) Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov 10(12):1808–1825PubMedPubMedCentralCrossRef
Shitara K, Ozguroglu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH et al (2018) Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 392(10142):123–133PubMedCrossRef
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D et al (2020a) Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 382(25):2419–2430PubMedCrossRef
Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW et al (2020b) Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol 6(10):1571–1580PubMedCrossRef
Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH et al (2021) Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. Ann Oncol 32(9):1127–1136PubMedCrossRef
Smith SM, Wachter K, Burris HA 3rd, Schilsky RL, George DJ, Peterson DE et al (2021) Clinical cancer advances 2021: ASCO’s report on progress against cancer. J Clin Oncol 39(10):1165–1184PubMedCrossRef
Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D et al (2016) Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v38–v49PubMedCrossRef
Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z et al (2017) Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. JAMA Oncol 3(9):1197–1203PubMedCrossRef
Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C (2014) The landscape of kinase fusions in cancer. Nat Commun 5:4846PubMedCrossRef
Strickler JH, Nakamura Y, Yoshino T, Catenacci DVT, Janjigian YY, Barzi A et al (2021) MOUNTAINEER-02: phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—trial in progress. J Clin Oncol 39(3_suppl):TPS252.
Sun K, Jia K, Lv H, Wang SQ, Wu Y, Lei H et al (2020) EBV-positive gastric cancer: current knowledge and future perspectives. Front Oncol 10:583463PubMedPubMedCentralCrossRef
Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K et al (2018) Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol 19(10):1372–1384PubMedCrossRef
Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E et al (2017) Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut 66(5):794–801PubMedCrossRef
Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H et al (2017) Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol 18(5):640–653PubMedCrossRef
Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D et al (2019) A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol 30(9):1487–1495PubMedPubMedCentralCrossRef
Van Campenhout C, Meléndez B, Remmelink M, Salmon I, D’Haene N (2019) Blood tumor mutational burden: are we ready for clinical implementation? J Thorac Dis 11(Suppl 15):S1906-s1908PubMedPubMedCentralCrossRef
Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC et al (2015) HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18(3):476–484PubMedCrossRef
van Velzen MJM, Derks S, van Grieken NCT, Haj Mohammad N, van Laarhoven HWM (2020) MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. Cancer Treat Rev 86:102024PubMedCrossRef
Wainberg ZA, Enzinger PC, Kang Y-K, Yamaguchi K, Qin S, Lee K-W et al (2021a) Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT). J Clin Oncol 39(3_suppl):160
Wainberg ZA, Fuchs CS, Tabernero J, Shitara K, Muro K, Van Cutsem E et al (2021b) Efficacy of pembrolizumab monotherapy for advanced gastric/gastroesophageal junction cancer with programmed death ligand 1 combined positive score ≥10. Clin Cancer Res 27(7):1923–1931PubMedCrossRef
Wang L, Ajani JA (2019c) Ushering in liquid biopsy for the microsatellite status: advantages and caveats. Clin Cancer Res 25(23):6887–6889PubMedCrossRef
Wang H, Li B, Liu Z, Gong J, Shao L, Ren J et al (2018) HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. Eur J Cancer 88:92–100PubMedCrossRef
Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH et al (2019a) Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol 30(9):1479–1486PubMedPubMedCentralCrossRef
Wang Z, Duan J, Cai S, Han M, Dong H, Zhao J et al (2019b) Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA Oncol 5(5):696–702PubMedPubMedCentralCrossRef
Wyrwicz LS, Lee KW, Van Cutsem E, Bang YJ, Fuchs CS, Kudaba I et al (2020) 1442P Association of TMB using the foundation medicine companion diagnostic (F1CDx) with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (pembro + chemo) versus chemo in patients with gastric cancer (gc) from KEYNOTE-062. Ann Oncol 31:S907–S908CrossRef
Xie T, Liu Y, Zhang Z, Zhang X, Gong J, Qi C et al (2020) Positive status of Epstein-Barr virus as a biomarker for gastric cancer immunotherapy: a prospective observational study. J Immunother 43(4):139–144PubMedPubMedCentralCrossRef
Yang J, Gong Y, Lam VK, Shi Y, Guan Y, Zhang Y et al (2020) Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death Dis 11(5):346PubMedPubMedCentralCrossRef
Zhang J, Dong R, Shen L (2020) Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer. Chin J Cancer Res 32(2):263–270PubMedPubMedCentralCrossRef
Metadaten
Titel
Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer
verfasst von
Nicole M. Myer
Kohei Shitara
Hyun C. Chung
Florian Lordick
Ronan J. Kelly
Zsolt Szabo
Z. Alexander Cao
Stephen Leong
David H. Ilson
Wilko Weichert
Publikationsdatum
13.05.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2022
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-021-03902-1

Weitere Artikel der Ausgabe 8/2022

Journal of Cancer Research and Clinical Oncology 8/2022 Zur Ausgabe

Original Article – Cancer Research

First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study

Original Article – Clinical Oncology

Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience

Review – Cancer Research

An approach to p32/gC1qR/HABP1: a multifunctional protein with an essential role in cancer

Original Article – Cancer Research

Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS

Original Article – Cancer Research

Regulatory network identified by pulmonary transcriptome and proteome profiling reveals extensive change of tumor-related genes in microRNA-21 knockout mice

Letter to the Editors

Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise